In all, 18 patients (30–56 years; median 49) with MDS underwent allogeneic HSCT from related (n=12) or unrelated (n=6) donors after a conditioning regimen comprising thiotepa, cyclophosphamide ...

The Food and Drug Administration (FDA) has approved Tepylute, a ready-to-dilute formulation of thiotepa. Tepylute is an alkylating drug indicated for the treatment of adenocarcinoma of the breast ...